Send to

Choose Destination
J Chemother. 2018 Jul;30(4):233-239. doi: 10.1080/1120009X.2018.1487150. Epub 2018 Jul 20.

Poor in vivo efficacy of caspofungin, micafungin and amphotericin B against wild-type Candida krusei clinical isolates does not correlate with in vitro susceptibility results.

Author information

a Faculty of Medicine, Department of Pulmonology , University of Debrecen , Debrecen , Hungary.
b Faculty of Medicine, Department of Medical Microbiology , University of Debrecen , Debrecen , Hungary.
c Faculty of Pharmacy , University of Debrecen , Debrecen , Hungary.
d Faculty of Dentistry , University of Debrecen , Debrecen , Hungary.


We determined micafungin, caspofungin and amphotericin B (AMB) minimum inhibitory concentration (MICs) and killing rates in RPMI-1640 and in RPMI-1640 with 50% serum against three Candida krusei bloodstream isolates. MIC ranges in RPMI-1640 were 0.125-0.25, 0.25 and 0.125-0.5 mg/L, in RPMI-1640 with 50% serum, MICs were 64-128-, 8- and 4-16-fold higher, respectively. In RPMI-1640 micafungin and caspofungin at 1, 4, 16 and 32 mg/L as well as AMB at 2 mg/L were fungicidal against all isolates in ≤3.96, ≤4.42 and 14.96 h, respectively. In RPMI-1640 with 50% serum, caspofungin was fungicidal for all isolates only at 32 mg/L, micafungin and AMB were fungistatic. In neutropenic mice, 5 mg/kg caspofungin and 1 mg/kg AMB were ineffective against two of the three isolates. Thus, in vivo efficacy of echinocandins and AMB is weak or absent against C. krusei. Prescribers treating C. krusei infections with echinocandins should watch out for clinical resistance and therapeutic failure.


50% serum; Echinocandin susceptibility; killing rate; neutropenic murine model

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center